CA2211262A1 - Micellar nanoparticles - Google Patents

Micellar nanoparticles

Info

Publication number
CA2211262A1
CA2211262A1 CA002211262A CA2211262A CA2211262A1 CA 2211262 A1 CA2211262 A1 CA 2211262A1 CA 002211262 A CA002211262 A CA 002211262A CA 2211262 A CA2211262 A CA 2211262A CA 2211262 A1 CA2211262 A1 CA 2211262A1
Authority
CA
Canada
Prior art keywords
micellar nanoparticles
micellar
nanoparticles
hydrating
estradiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002211262A
Other languages
French (fr)
Other versions
CA2211262C (en
Inventor
D. Craig Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Graceway Pharmaceuticals LLC
Original Assignee
Novavax, Inc.
D. Craig Wright
Graceway Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax, Inc., D. Craig Wright, Graceway Pharmaceuticals, Llc filed Critical Novavax, Inc.
Publication of CA2211262A1 publication Critical patent/CA2211262A1/en
Application granted granted Critical
Publication of CA2211262C publication Critical patent/CA2211262C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915Therapeutic or pharmaceutical composition
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926Topical chemical, e.g. cosmetic or sunscreen

Abstract

The present invention relates to micellar nanoparticles and methods of their production. Micellar nanoparticles are made by hydrating a mixture of an oil, a stabilizer/surfactant, and an alcoholic initiator with an aqueous solution. These micellar nanoparticles are normally less than 100 nanometers in diameter. The micellar nanoparticles are particularly advantageous in delivering materials such as estradiol topically through the skin because their small size allows easy penetration.
CA002211262A 1995-01-31 1996-01-29 Micellar nanoparticles Expired - Fee Related CA2211262C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/380,942 1995-01-31
US08/380,942 US5629021A (en) 1995-01-31 1995-01-31 Micellar nanoparticles
PCT/US1996/001410 WO1996023409A1 (en) 1995-01-31 1996-01-29 Micellar nanoparticles

Publications (2)

Publication Number Publication Date
CA2211262A1 true CA2211262A1 (en) 1996-08-08
CA2211262C CA2211262C (en) 2005-08-30

Family

ID=23503042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002211262A Expired - Fee Related CA2211262C (en) 1995-01-31 1996-01-29 Micellar nanoparticles

Country Status (14)

Country Link
US (1) US5629021A (en)
EP (1) EP0806894B1 (en)
JP (1) JP3974170B2 (en)
KR (1) KR100482390B1 (en)
CN (1) CN1144583C (en)
AU (1) AU711744B2 (en)
BR (1) BR9606996A (en)
CA (1) CA2211262C (en)
DE (1) DE69627309T2 (en)
DK (1) DK0806894T3 (en)
ES (1) ES2200055T3 (en)
PT (1) PT806894E (en)
WO (1) WO1996023409A1 (en)
ZA (1) ZA96738B (en)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387373B1 (en) * 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US6542183B1 (en) 1995-06-28 2003-04-01 Lynx Systems Developers, Inc. Event recording apparatus
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
KR100342835B1 (en) * 1998-07-31 2002-07-02 박호군 Lipid emulsion as a gene or drug carrier, formulation, and method for preparating thereof
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
MXPA01007895A (en) 1999-02-03 2003-07-21 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US8236335B2 (en) 1999-04-28 2012-08-07 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
EP1267946A4 (en) 2000-02-28 2008-07-02 Genesegues Inc Nanocapsule encapsulation system and method
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
AU8206401A (en) 2000-08-03 2002-02-18 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6423707B1 (en) 2000-08-28 2002-07-23 California Pacific Medical Center Nitroimidazole ester analogues and therapeutic applications
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6537591B2 (en) 2001-03-02 2003-03-25 Aquarium Pharmaceuticals, Inc. Aquatic animal treatment method and composition containing Pimenta extract
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
WO2003020024A2 (en) * 2001-08-28 2003-03-13 Eden Research Plc Treatment and prevention of infections in plants
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8663687B2 (en) * 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
AU2002360517A1 (en) * 2001-12-07 2003-06-23 Ximed Group Plc Respiratory infection prevention and treatment with terpene-containing compositions
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US20030228402A1 (en) * 2002-02-19 2003-12-11 Franklin Lanny U. Compositions and methods for preservation of food
EP1487504A4 (en) * 2002-02-19 2010-09-01 Eden Research Plc Improvement of indoor air quality and antiseptic composition for use therein
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
DK1670433T3 (en) 2003-10-10 2012-03-12 Ferring Bv Transdermal pharmaceutical formulation to reduce skin remnants
US20050084456A1 (en) * 2003-10-21 2005-04-21 Liping Tang Functionalized particles
US20050084513A1 (en) * 2003-10-21 2005-04-21 Board Of Regents Nanocoating for improving biocompatibility of medical implants
AP2195A (en) 2004-01-23 2011-01-10 Eden Research Plc Methods of killing nematodes comprising the application of a terpene component.
CN1993113B (en) * 2004-02-13 2010-12-08 Nod药物公司 Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
EP2338332B1 (en) 2004-05-20 2014-02-12 Eden Research Plc Hollow glucan particle or cell wall particle encapsulating a terpene component
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006036982A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
US8858978B2 (en) 2004-09-28 2014-10-14 Atrium Medical Corporation Heat cured gel and method of making
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
WO2006050368A2 (en) 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
WO2006113668A1 (en) * 2005-04-15 2006-10-26 University Of South Florida A method of transdermal drug delivery using hyaluronic acid nanoparticles
WO2007124250A2 (en) * 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
JP5368793B2 (en) * 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル Compositions and methods for making and using nanoemulsions
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
ES2693745T3 (en) 2005-10-12 2018-12-13 Unimed Pharmaceuticals, Llc Improved testosterone gel for use in the treatment of hypogonadism
RU2483751C2 (en) 2005-10-18 2013-06-10 Новавакс, Инк. FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPs)
US10667512B2 (en) 2005-11-30 2020-06-02 Eden Research Plc Terpene-containing compositions and methods of making and using them
WO2007063268A1 (en) 2005-11-30 2007-06-07 Eden Research Plc Compositions and methods comprising terpenes or terpene mixtures selected from thymol, eugenol, geraniol, citral, and l-carvone
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
HUE043423T2 (en) 2005-12-01 2019-08-28 Univ Massachusetts Lowell Botulinum nanoemulsions
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
AU2007224006A1 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
WO2007123790A1 (en) * 2006-04-07 2007-11-01 Novavax, Inc. Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties
US9040250B2 (en) * 2006-09-07 2015-05-26 The United States Of America, As Represented By The Secretary Of The Navy Binding interaction of proanthocyanidins with bacteria and bacterial components
WO2008039864A1 (en) * 2006-09-26 2008-04-03 Novavax, Inc. Emulsion formulations for transdermal delivery of poorly water soluble active agents
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
CN101848702B (en) 2006-12-01 2013-07-17 安特里奥公司 Amphiphilic entity nanoparticles
KR20150028308A (en) * 2006-12-01 2015-03-13 안테리오스, 인코퍼레이티드 Peptide nanoparticles and uses therefor
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US20080207756A1 (en) * 2007-02-27 2008-08-28 Atrium Medical Corporation Bio-absorbable oil suspension
EP2152304B1 (en) 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
ES2660906T3 (en) 2007-05-31 2018-03-26 Anterios, Inc. Nucleic acid nanoparticles and uses thereof
PT2540312E (en) 2007-07-19 2015-08-31 Novavax Inc Avian influenza chimeric vlps
JP2011526302A (en) * 2008-06-26 2011-10-06 アンテリオス, インコーポレイテッド Transdermal delivery
US9974844B2 (en) 2008-11-17 2018-05-22 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
PT3067064T (en) 2008-12-09 2020-06-16 Novavax Inc Modified rsv f proteins and methods of their use
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010116382A2 (en) 2009-04-08 2010-10-14 Cadila Healthcare Limited Stable pharmaceutical compositions of diclofenac
US8470304B2 (en) 2009-08-04 2013-06-25 Avidas Pharmaceuticals Llc Therapeutic vitamin D sun-protecting formulations and methods for their use
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US20110045050A1 (en) * 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
MX2013004296A (en) 2010-10-21 2013-09-26 Cadila Healthcare Ltd Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis.
US9789123B2 (en) 2010-10-21 2017-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
WO2012053012A2 (en) 2010-10-21 2012-04-26 Cadila Healthcare Limited Topical pharmaceutical compositions comprising tfflocolchicoside
US20130295145A1 (en) 2010-10-21 2013-11-07 Cadila Healthcare Limited Topical pharmaceutical compositions comprising etodolac
WO2012053009A2 (en) 2010-10-21 2012-04-26 Cadila Healthcare Limited Pharmaceutical compositions comprising skin whitening agents
WO2012053013A2 (en) 2010-10-21 2012-04-26 Cadila Healthcare Limited Pharmaceutical compositions of anti-acne agents
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
WO2012059936A1 (en) 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
EP3246019B1 (en) 2010-11-05 2021-03-03 Novavax, Inc. Rabies glycoprotein virus-like particles (vlps)
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP2654793B1 (en) 2010-12-21 2017-09-13 Leidos, Inc. Methods and compositions for wound treatment
US20120189677A1 (en) * 2011-01-20 2012-07-26 Stephen Tonge Formulations
WO2012127496A1 (en) 2011-03-01 2012-09-27 Cadila Healthcare Limited Stable pharmaceutical compositions of lornoxicam or salts thereof
US11065206B2 (en) 2011-06-29 2021-07-20 Avidas Pharmaceuticals, LLC Topical formulations including lipid microcapsule delivery vehicles and their uses
WO2013014680A1 (en) 2011-07-28 2013-01-31 Cadila Healthcare Limited Method for treatment of pain and inflammation
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10322089B2 (en) * 2012-03-14 2019-06-18 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles, nanoparticle delivery methods, and systems of delivery
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
GB201220940D0 (en) 2012-11-21 2013-01-02 Eden Research Plc Method P
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016003419A (en) 2013-09-19 2016-10-10 Novavax Inc Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods.
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
SG10201902499VA (en) 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems
US10894024B2 (en) * 2014-12-08 2021-01-19 Synaptamine, Inc. Anti-RDS compounds and method of manufacture and administration thereof to induce dopamine homeostatis
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN108697790B (en) 2015-09-03 2022-02-18 诺瓦瓦克斯股份有限公司 Vaccine compositions with improved stability and immunogenicity
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
BR112019010131A2 (en) 2016-11-21 2019-10-08 Eirion Therapeutics Inc transdermal delivery of large agents
WO2018098501A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
EP3658118A4 (en) 2017-07-24 2021-03-31 Novavax, Inc. Methods and compositions for treating respiratory disease
CN110881462A (en) * 2019-11-25 2020-03-17 南京启佑生物科技有限公司 Nano pesticide composite preparation based on phosphate and metal ions and preparation method thereof
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE43327T1 (en) * 1980-07-01 1983-01-05 L'Oreal, 75008 Paris METHOD FOR PRODUCING STABLE DISPERSIONS IN AN AQUEOUS PHASE OF AT LEAST ONE LIQUID, NOT WATER-MISCIPABLE, AND THE CORRESPONDING DISPERSIONS.
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
DE3919982A1 (en) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh ORAL LIPID MEDICINE FORM
CH677886A5 (en) * 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
AU658608B2 (en) * 1991-03-25 1995-04-27 Astellas Pharma Europe B.V. Topical preparation containing a suspension of solid lipid particles

Also Published As

Publication number Publication date
CN1144583C (en) 2004-04-07
DK0806894T3 (en) 2003-08-04
EP0806894A1 (en) 1997-11-19
CN1179698A (en) 1998-04-22
KR100482390B1 (en) 2005-08-31
AU4970996A (en) 1996-08-21
CA2211262C (en) 2005-08-30
DE69627309D1 (en) 2003-05-15
EP0806894B1 (en) 2003-04-09
PT806894E (en) 2003-08-29
EP0806894A4 (en) 1999-12-15
DE69627309T2 (en) 2004-03-04
US5629021A (en) 1997-05-13
KR19980701770A (en) 1998-06-25
JP3974170B2 (en) 2007-09-12
AU711744B2 (en) 1999-10-21
MX9705663A (en) 1998-07-31
BR9606996A (en) 1997-10-28
ZA96738B (en) 1996-09-26
ES2200055T3 (en) 2004-03-01
JPH10513185A (en) 1998-12-15
WO1996023409A1 (en) 1996-08-08

Similar Documents

Publication Publication Date Title
CA2211262A1 (en) Micellar nanoparticles
CA2145818A1 (en) Soft single-ply tissue having very low sidedness
CA2339482A1 (en) Composite hydrogel drug delivery systems
CA2463172A1 (en) Polymeric micelle composition with improved stability
WO2002056843A3 (en) Translucent nanoemulsion, production method, and uses thereof in the cosmetic, dermatological and/or ophthalmological fields
WO2004054499A3 (en) Platinum aggregates and process for producing the same
NO992068D0 (en) Microemulsion and process for its preparation
CA2260185A1 (en) Hormone replacement therapy drug formulations for topical application to the skin
CA2164050A1 (en) Cosmetic compositions containing betulinic acid
AU4327193A (en) Liposomes, method of preparing them and their use in the preparation of drugs
EP1281722A4 (en) Hyaluronic acid gel, process for producing the same, and medical material containing the same
AU2416188A (en) Improved amphotericin b liposome preparation
AU2002226916A1 (en) Fabric color care method
CA2397198A1 (en) Echinacea extract as anti-irritant and anti-aging booster in cosmetic compositions
CA2000960A1 (en) Insecticide
CA2026304A1 (en) Citrus oil compositions with uses thereof
NZ508960A (en) Method of forming liposomes
EP2093208A3 (en) Process for the preparation of 3,3-dimethylbutanal
WO1997007786A3 (en) Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process
CA2359644A1 (en) Golf club and method of manufacturing the same
RU94035673A (en) Gel composition for use in cosmetics and dermatology
ATE356617T1 (en) METHOD FOR PRODUCING A WATER-INSOLUBLE AMORPHIC RETARD MATRIX
CA2019117A1 (en) Aqueous dispersions of polyester and polyesteramides cross-linked with metallic ions and casts made therefrom
CA2406398A1 (en) Roll formed staple-in awning frame and method
CA2371917A1 (en) After shave composition containing aluminum chlorohydrate

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed